U.S. Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Formulation (Cream, Gel, Spray, Patch, and Others), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), and Distribution Channel (Pharmacies & Drug Stores, E-Commerce, and Retail & Grocery Stores): Opportunity Analysis and Industry Forecast, 2020–2027

January 2021 | 128 pages | ID: U15E347165EEN
Allied Market Research

Abstracts

The U.S. topical pain relief market was valued at $2,612 million in 2019, and is projected to reach $3,272 million by 2027 at a CAGR of 3.7% from 2020 to 2027.

Pain is a distressing feeling caused by intense or damaging stimuli and it is one of the most common reasons for physician consultation in the U.S. Analgesics or painkillers are used to reduce and treat body pain. Whenever these analgesics are applied directly to the skin they are known as topical pain relief medications. These include topical administration of drugs such as non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, and opioids. Topical pain relief medications exert peripheral effects near the site of application and minimize the pain.

Increase in prevalence of arthritis and joint pain is the major factor that contributes toward the growth of the topical pain relief market in the U.S. Moreover, other factors that fuel the market growth include growth in geriatric population, lesser side effects caused due to use of topical analgesics as compared to oral pain relief, wide availability of topical pain relieving drugs, and high demand for topical pain relief by sports players. However, topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that impede the market growth. Conversely, development of online platform for the topical therapeutics is expected to provide lucrative opportunities for the market growth.

The U.S. topical pain relief market is segmented into therapeutic class, type, formulation, and distribution channel. On the basis of therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. On the basis of type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. On the basis of formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Therapeutic Class

• Non-opioids
• Nonsteroidal anti-inflammatory drug (NSAIDS)
• Methyl Salicylate
• Capsaicin
• Lidocaine
• Other Non-opioids
• Opioids
• Buprenorphine
• Fentanyl

By Formulation

• Cream
• Gel
• Spray
• Patch
• Others

By Type

• Prescription Pain Relief
• Over-the-counter (OTC) Pain Relief

By Distribution Channel

• Pharmacy & Drug Store
• e-Commerce
• Retail & Grocery Store

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• AdvaCare Pharma
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Nestl? S.A.
• Novartis AG
• Pfizer Inc.
• Reckitt Benckiser Group plc
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Topical BioMedics, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

• Cipla Limited
• Glenmark Pharmaceuticals Limited

Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
  1.4.1.Secondary research
  1.4.2.Primary research
  1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
  3.2.1.Top investment pockets
3.3.Porter’s five force analysis
3.4.Market dynamics
  3.4.1.Drivers
    3.4.1.1.Increase in prevalence of arthritis
    3.4.1.2.Growth in geriatric population
    3.4.1.3.High demand for topical pain relief products by sportsperson
    3.4.1.4.Lesser side effects caused by topical pain relief products as compared to oral medicines
  3.4.2.Restraints
    3.4.2.1.Topical pain relief sometimes cause skin irritants
    3.4.2.2.Topical pain relief is characterized by unpleasant odor
  3.4.3.Opportunities
    3.4.3.1.Emergence of online pharmacy
  3.4.4.Impact analysis
3.5.COVID-19 Impact analysis on U.S. topical pain relief market

CHAPTER 4:U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS

4.1.Overview
  4.1.1.Market size and forecast
4.2.Non-opioids
  4.2.1.Key market trends, growth factors and opportunities
  4.2.2.Market size and forecast, by type
    4.2.2.1.Nonsteroidal anti-inflammatory drugs (NSAIDS)
      4.2.2.1.1.Market size and forecast
    4.2.2.2.Methyl salicylates
      4.2.2.2.1.Market size and forecast
    4.2.2.3.Capsaicin
      4.2.2.3.1.Market size and forecast
    4.2.2.4.Lidocaine
      4.2.2.4.1.Market size and forecast
    4.2.2.5.Other non-opioids
      4.2.2.5.1.Market size and forecast
4.3.Opioids
  4.3.1.Key market trends, growth factors and opportunities
  4.3.2.Market size and forecast, by type
    4.3.2.1.Buprenorphine
      4.3.2.1.1.Market size and forecast
    4.3.2.2.Fentanyl
      4.3.2.2.1.Market size and forecast

CHAPTER 5:U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION

5.1.Overview
  5.1.1.Market size and forecast
5.2.Cream
  5.2.1.Market size and forecast
5.3.Gel
  5.3.1.Market size and forecast
5.4.Spray
  5.4.1.Market size and forecast
5.5.Patch
  5.5.1.Market size and forecast
5.6.Others
  5.6.1.Market size and forecast

CHAPTER 6:U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE

6.1.Overview
  6.1.1.Market size and forecast
6.2.Prescription pain relief
  6.2.1.Market size and forecast
6.3.Over-the-counter pain relief
  6.3.1.Market size and forecast

CHAPTER 7:U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL

7.1.Overview
  7.1.1.Market size and forecast
7.2.Pharmacies & drug stores
  7.2.1.Market size and forecast
7.3.E-Commerce
  7.3.1.Market size and forecast
7.4.Retail & grocery stores
  7.4.1.Market size and forecast

CHAPTER 8:COMPANY PROFILES

8.1.ADVACARE PHARMA
  8.1.1.Company overview
  8.1.2.Company snapshot
  8.1.3.Operating business segments
  8.1.4.Product Portfolio
8.2.GLAXOSMITHKLINE PLC (GSK)
  8.2.1.Company overview
  8.2.2.Company snapshot
  8.2.3.Operating business segments
  8.2.4.Product portfolio
  8.2.5.Business performance
  8.2.6.Key strategic moves and developments
8.3.JOHNSON & JOHNSON
  8.3.1.Company overview
  8.3.2.Company snapshot
  8.3.3.Operating business segments
  8.3.4.Product portfolio
  8.3.5.Business performance
8.4.NESTL? S.A.
  8.4.1.Company overview
  8.4.2.Company snapshot
  8.4.3.Operating business segments
  8.4.4.Product Portfolio
  8.4.5.Business performance
8.5.NOVARTIS AG
  8.5.1.Company overview
  8.5.2.Company snapshot
  8.5.3.Operating business segments
  8.5.4.Product portfolio
  8.5.5.Business performance
8.6.PFIZER INC.
  8.6.1.Company overview
  8.6.2.Company snapshot
  8.6.3.Operating business segments
  8.6.4.Product portfolio
  8.6.5.Business performance
8.7.RECKITT BENCKISER GROUP PLC
  8.7.1.Company overview
  8.7.2.Company snapshot
  8.7.3.Operating business segments
  8.7.4.Product Portfolio
  8.7.5.Business performance
8.8.SANOFI
  8.8.1.Company overview
  8.8.2.Company snapshot
  8.8.3.Operating business segments
  8.8.4.Product portfolio
  8.8.5.Business performance
8.9.SUN PHARMACEUTICAL INDUSTRIES LTD.
  8.9.1.Company overview
  8.9.2.Company snapshot
  8.9.3.Operating business segments
  8.9.4.Product portfolio
  8.9.5.Business performance
8.10.TOPICAL BIOMEDICS, INC.
  8.10.1.Company overview
  8.10.2.Company snapshot
  8.10.3.Operating business segments
  8.10.4.Product Portfolio

List Of Tables

LIST OF TABLES

TABLE 01.U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 02.U.S. TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 03.U.S. TOPICAL OPIOIDS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 04.U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 05.U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 06.U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 07.ADVACARE: COMPANY SNAPSHOT
TABLE 08.ADVACARE: BUSINESS SEGMENTS
TABLE 09.ADVACARE: PRODUCT PORTFOLIO
TABLE 10.GSK: COMPANY SNAPSHOT
TABLE 11.GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 12.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 13.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14.J&J: COMPANY SNAPSHOT
TABLE 15.J&J: OPERATING SEGMENTS
TABLE 16.J&J: PRODUCT PORTFOLIO
TABLE 17.NESTL?: COMPANY SNAPSHOT
TABLE 18.NESTL?: OPERATING SEGMENTS
TABLE 19.NESTL?: PRODUCT PORTFOLIO
TABLE 20.NOVARTIS: COMPANY SNAPSHOT
TABLE 21.NOVARTIS: OPERATING SEGMENT
TABLE 22.NOVARTIS: PRODUCT PORTFOLIO
TABLE 23.PFIZER: COMPANY SNAPSHOT
TABLE 24.PFIZER: OPERATING SEGMENT
TABLE 25.PFIZER: PRODUCT PORTFOLIO
TABLE 26.RB: COMPANY SNAPSHOT
TABLE 27.RB: OPERATING SEGMENTS
TABLE 28.RB: PRODUCT PORTFOLIO
TABLE 29.SANOFI: COMPANY SNAPSHOT
TABLE 30.SANOFI: OPERATING SEGMENT
TABLE 31.SANOFI: PRODUCT PORTFOLIO
TABLE 32.SUN PHARMA: COMPANY SNAPSHOT
TABLE 33.SUN PHARMA: OPERATING SEGMENTS
TABLE 34.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 35.TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 36.TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 37.TOPICAL BIOMEDICS: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01.U.S. TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.HIGH BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.NUMBER OF ELDERLY POPULATION (ADULT 65+) IN THE U.S., 2020-2060 (MILLION)
FIGURE 09.IMPACT ANALYSIS: U.S. TOPICAL PAIN RELIEF MARKET
FIGURE 10.U.S. TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, 2019–2027 ($MILLION)
FIGURE 11.U.S. TOPICAL METHYL SALICYLATES MARKET, 2019–2027 ($MILLION)
FIGURE 12.U.S. TOPICAL CAPSAICIN MARKET, 2019–2027 ($MILLION)
FIGURE 13.U.S. TOPICAL LIDOCAINE MARKET, 2019–2027 ($MILLION)
FIGURE 14.U.S. TOPICAL OTHER NON-OPIOIDS MARKET, 2019–2027 ($MILLION)
FIGURE 15.U.S. TOPICAL BUPRENORPHINE MARKET, 2019–2027 ($MILLION)
FIGURE 16.U.S. TOPICAL FENTANYL MARKET, 2019–2027 ($MILLION)
FIGURE 17.U.S. TOPICAL PAIN RELIEF CREAM MEDICATIONS MARKET, 2019–2027 ($MILLION)
FIGURE 18.U.S. TOPICAL PAIN RELIEF GEL MARKET, 2019–2027 ($MILLION)
FIGURE 19.U.S. TOPICAL PAIN RELIEF SPRAY MARKET, 2019–2027 ($MILLION)
FIGURE 20.U.S. TOPICAL PAIN RELIEF PATCH MARKET, 2019–2027 ($MILLION)
FIGURE 21.U.S. OTHERS TOPICAL PAIN RELIEF MARKET, 2019–2027 ($MILLION)
FIGURE 22.U.S. PRESCRIPTION PAIN RELIEF TOPICAL PAIN RELIEF MARKET, 2019–2027 ($MILLION)
FIGURE 23.U.S. PHARMACIES & DRUG STORES TOPICAL PAIN RELIEF MARKET, 2019–2027 ($MILLION)
FIGURE 24.U.S. E-COMMERCE TOPICAL PAIN RELIEF MARKET, 2019–2027 ($MILLION)
FIGURE 25.U.S. RETAIL & GROCERY STORES TOPICAL PAIN RELIEF MARKET, 2019–2027 ($MILLION)
FIGURE 26.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.GSK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.GSK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 31.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 32.NESTL?: REVENUE, 2017–2019 ($MILLION)
FIGURE 33.NESTL?: REVENUE SHARE BY OPERATING SEGMENT, 2019 (%)
FIGURE 34.NESTL?.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 35.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 37.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 38.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.PFIZER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 40.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 41.RB: REVENUE, 2017–2019 ($MILLION)
FIGURE 42.RB: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 43.RB: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 44.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 46.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 47.SUN PHARMA: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.SUN PHARMA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 49.SUN PHARMA: REVENUE SHARE BY REGION, 2019 (%)